Krishna Murthy, MD
Internal Medicine · Princeton, INNPI 1841293115
Payments from drug & device makers
Across 235 payments — averaging $24.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$679
- AstraZeneca$621
- Amgen$559
- Bayer$526
- Lilly USA, LLC$507
- Novo Nordisk$505
- plus $2K from 34 others
What the payments were for
- Food & beverage$5,77098%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $679 |
| AstraZeneca | 20 | $621 |
| Amgen | 17 | $559 |
| Bayer | 10 | $526 |
| Lilly USA, LLC | 35 | $507 |
| Novo Nordisk | 25 | $505 |
| Abbott | 5 | $218 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $210 |
| Teva Pharmaceuticals USA, Inc. | 5 | $175 |
| Pfizer | 11 | $154 |
| E.r. Squibb & Sons, L.L.C. | 2 | $143 |
| Travere Therapeutics, Inc. | 1 | $125 |
| United Therapeutics Corporation | 1 | $123 |
| Novartis | 6 | $122 |
| Genentech USA, Inc. | 2 | $113 |
| Exact Sciences | 7 | $105 |
| Merck | 4 | $101 |
| Nevro Corp. | 1 | $101 |
| AbbVie | 6 | $92 |
| Mylan Specialty L.p. | 5 | $85 |
| Boehringer Ingelheim | 6 | $82 |
| Edwards Lifesciences | 1 | $80 |
| Medtronic | 1 | $52 |
| Astellas Pharma US Inc | 3 | $46 |
| Sunovion Pharmaceuticals Inc. | 3 | $40 |
| Boston Scientific | 1 | $36 |
| Covis Pharma GmbH | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 2 | $26 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $24 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Verona Pharma, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $17 |
| Corium, LLC | 2 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$249
- XIENCE SKYPOINT$145
- SYMBICORT$132
- CAMZYOS$128
- Prolia$125
- ArmonAir Digihaler$123
- AirDuo RespiClick$123
- ProAir Digihaler$123
- AREXVY$123
- TYVASO$123
- TRELEGY ELLIPTA$110
- AIMOVIG$109
- Omnia$101
How this compares
$5,870 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $49,828 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $32,645 |
| Incruse ElliptaUmeclidinium Bromide | 53 | $22,308 |
| Spiriva RespimatTiotropium Bromide | 27 | $16,393 |
| JanuviaSitagliptin Phosphate | 16 | $15,159 |
| Spiriva HandihalerTiotropium Bromide | 22 | $13,986 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $13,290 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $10,636 |
| XareltoRivaroxaban | 13 | $8,041 |
| Arnuity ElliptaFluticasone Furoate | 22 | $7,671 |
| EntrestoSacubitril/Valsartan | 14 | $7,556 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $7,113 |
| DuleraMometasone/Formoterol | 14 | $4,815 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $4,244 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $3,492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $679 | $125,741245 claims |
| MerckJanuvia, Janumet Xr, Dulera | $101 | $30,61047 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $82 | $23,50640 claims |
| Johnson & JohnsonXarelto | $24 | $8,04113 claims |
| NovartisEntresto | $122 | $7,55614 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $175 | $83813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Princeton
- Robert BuynakValparaiso$24.2M
- Mohammed AllawNewburgh$3.6M
- Raj VuppalanchiIndianapolis$3.4M
- Phillip TothIndianapolis$3.2M
- George CornettFranklin$1.3M
- Ajita NarayanLafayette$951K
- Abhinav SinghGreenwood$738K
- Georgiann LinnemeierIndianapolis$692K
- Wa'el BakdashAnderson$625K
- Rita SchmidSouth Bend$599K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.